• mail icon
  • fb icon
  • linkedin icon

Investors

Past Events

Eiger Business Update Call
June 29, 2023
PARTICIPANT DIAL IN (TOLL FREE): 1-866-524-3160
PARTICIPANT INTERNATIONAL DIAL IN: 1-412-317-6760
Analyst / HDV KOL Meeting
May 18, 2016
Speakers will include Dr. Jeffrey Glenn and Dr. Cihan Yurdaydin. Discussions will include an update of LOWR HDV-2 data post-EASL.

New York City, NY,
United States

EASL
April 15, 2016
1) Dahari, H. et al; “Hepatitis delta virus (HDV) kinetics under the prenylation inhibitor lonafarnib suggest HDV-mediated suppression of the HBV replication.” Poster FRI-111. 2) Dahari, H. et al; “Pharmacokinetics and pharmacodynamics modeling of lonafarnib in patients with chronic hepatitis delta virus infection.” Poster FRI-115.

Barcelona, Spain,
United States

European Association for the Study of the Liver (EASL) Meeting
April 13, 2016
• Yurdaydin, C. et al; “Exploring optimal dosing of lonafarnib with ritonavir for the treatment of chronic delta hepatitis — results from the on-going LOWR HDV – 2 study.” Oral Presentation, Hepatitis Delta International Network (HDIN) at EASL • Dahari, H. et al; “Hepatitis delta virus (HDV) kinetics under the prenylation inhibitor lonafarnib suggest HDV-mediated suppression of the HBV replication.” Poster Presentation. • Dahari, H. et al; “Pharmacokinetics and pharmacodynamics modeling of lonafarnib in patients with chronic hepatitis delta virus infection.” Poster Presentation.
Hepatitis Delta International Network (HDIN)
April 13, 2016
Dr. Cihan Yurdaydin: “Exploring optimal dosing of lonafarnib with ritonavir for the treatment of chronic delta hepatitis — results from the on-going LOWR HDV - 2 study.” Oral; 4:15-4:30 pm

Barcelona, Spain,
United States